These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 24139027)

  • 1. Anti-tau antibodies: hitting the target.
    Golde TE; Lewis J; McFarland NR
    Neuron; 2013 Oct; 80(2):254-6. PubMed ID: 24139027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurodegenerative disease: Tau immunotherapy targets transcellular propagation.
    Flight MH
    Nat Rev Drug Discov; 2013 Dec; 12(12):904. PubMed ID: 24232374
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo.
    Yanamandra K; Kfoury N; Jiang H; Mahan TE; Ma S; Maloney SE; Wozniak DF; Diamond MI; Holtzman DM
    Neuron; 2013 Oct; 80(2):402-414. PubMed ID: 24075978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy.
    Congdon EE; Chukwu JE; Shamir DB; Deng J; Ujla D; Sait HBR; Neubert TA; Kong XP; Sigurdsson EM
    EBioMedicine; 2019 Apr; 42():157-173. PubMed ID: 30910484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy.
    Kondo A; Shahpasand K; Mannix R; Qiu J; Moncaster J; Chen CH; Yao Y; Lin YM; Driver JA; Sun Y; Wei S; Luo ML; Albayram O; Huang P; Rotenberg A; Ryo A; Goldstein LE; Pascual-Leone A; McKee AC; Meehan W; Zhou XZ; Lu KP
    Nature; 2015 Jul; 523(7561):431-436. PubMed ID: 26176913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies.
    Clavaguera F; Grueninger F; Tolnay M
    Neuropharmacology; 2014 Jan; 76 Pt A():9-15. PubMed ID: 24050961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.
    Castillo-Carranza DL; Gerson JE; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Kayed R
    J Alzheimers Dis; 2014; 40 Suppl 1():S97-S111. PubMed ID: 24603946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.
    Theunis C; Adolfsson O; Crespo-Biel N; Piorkowska K; Pihlgren M; Hickman DT; Gafner V; Borghgraef P; Devijver H; Pfeifer A; Van Leuven F; Muhs A
    J Alzheimers Dis; 2017; 56(2):585-599. PubMed ID: 28035925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate.
    Bondulich MK; Guo T; Meehan C; Manion J; Rodriguez Martin T; Mitchell JC; Hortobagyi T; Yankova N; Stygelbout V; Brion JP; Noble W; Hanger DP
    Brain; 2016 Aug; 139(Pt 8):2290-306. PubMed ID: 27297240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.
    Strang KH; Goodwin MS; Riffe C; Moore BD; Chakrabarty P; Levites Y; Golde TE; Giasson BI
    Acta Neuropathol Commun; 2017 Jul; 5(1):58. PubMed ID: 28760159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo.
    Vandermeeren M; Borgers M; Van Kolen K; Theunis C; Vasconcelos B; Bottelbergs A; Wintmolders C; Daneels G; Willems R; Dockx K; Delbroek L; Marreiro A; Ver Donck L; Sousa C; Nanjunda R; Lacy E; Van De Casteele T; Van Dam D; De Deyn PP; Kemp JA; Malia TJ; Mercken MH
    J Alzheimers Dis; 2018; 65(1):265-281. PubMed ID: 30040731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligomeric tau-targeted immunotherapy in Tg4510 mice.
    Schroeder S; Joly-Amado A; Soliman A; Sengupta U; Kayed R; Gordon MN; Morgan D
    Alzheimers Res Ther; 2017 Jun; 9(1):46. PubMed ID: 28655349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Overview on the Clinical Development of Tau-Based Therapeutics.
    Medina M
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29641484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency.
    Agadjanyan MG; Zagorski K; Petrushina I; Davtyan H; Kazarian K; Antonenko M; Davis J; Bon C; Blurton-Jones M; Cribbs DH; Ghochikyan A
    Mol Neurodegener; 2017 May; 12(1):33. PubMed ID: 28472993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Status of Clinical Trials on Tau Immunotherapies.
    Ji C; Sigurdsson EM
    Drugs; 2021 Jul; 81(10):1135-1152. PubMed ID: 34101156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau immunotherapies: Lessons learned, current status and future considerations.
    Sandusky-Beltran LA; Sigurdsson EM
    Neuropharmacology; 2020 Sep; 175():108104. PubMed ID: 32360477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy.
    Wang X; Smith K; Pearson M; Hughes A; Cosden ML; Marcus J; Hess JF; Savage MJ; Rosahl T; Smith SM; Schachter JB; Uslaner JM
    PLoS One; 2018; 13(4):e0195486. PubMed ID: 29624602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.
    Javidnia M; Hebron ML; Xin Y; Kinney NG; Moussa CE
    J Alzheimers Dis; 2017; 60(2):461-481. PubMed ID: 28869476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies.
    Wagner J; Krauss S; Shi S; Ryazanov S; Steffen J; Miklitz C; Leonov A; Kleinknecht A; Göricke B; Weishaupt JH; Weckbecker D; Reiner AM; Zinth W; Levin J; Ehninger D; Remy S; Kretzschmar HA; Griesinger C; Giese A; Fuhrmann M
    Acta Neuropathol; 2015 Nov; 130(5):619-31. PubMed ID: 26439832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls.
    Sigurdsson EM
    J Alzheimers Dis; 2018; 64(s1):S555-S565. PubMed ID: 29865056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.